High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$1.2M
$1,181,087
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
| KALV |
KalVista Pharmaceuticals, Inc.
|
CEO
Sell to Cover
|
2026-03-09 | $107,633 | S | Form 4 |
|
KALV
S
KalVista Pharmaceuticals, Inc.
Audhya Paul K.
• Officer • CHIEF MEDICAL OFFICER
Sell to Cover
2026-02-23
$83,345
|
||||||
| KALV |
KalVista Pharmaceuticals, Inc.
|
Officer • CHIEF MEDICAL OFFICER
Sell to Cover
|
2026-02-23 | $83,345 | S | Form 4 |
| KALV |
KalVista Pharmaceuticals, Inc.
|
CEO
Sell to Cover
|
2026-02-23 | $156,197 | S | Form 4 |
|
KALV
S
KalVista Pharmaceuticals, Inc.
Piekos Brian
• CFO
Sell to CoverΔOwn -11.4%
2026-02-23
$27,507
|
||||||
| KALV |
KalVista Pharmaceuticals, Inc.
|
CFO
Sell to CoverΔOwn -11.4%
|
2026-02-23 | $27,507 | S | Form 4 |
|
KALV
S
KalVista Pharmaceuticals, Inc.
Sweeny Nicole
• Officer • Chief Commercial Officer
Sell to Cover
2026-02-23
$61,878
|
||||||
| KALV |
KalVista Pharmaceuticals, Inc.
|
Officer • Chief Commercial Officer
Sell to Cover
|
2026-02-23 | $61,878 | S | Form 4 |
|
KALV
S
KalVista Pharmaceuticals, Inc.
Yea Christopher
• Officer • CHIEF DEVELOPMENT OFFICER
Sell to Cover
2026-02-23
$67,669
|
||||||
| KALV |
KalVista Pharmaceuticals, Inc.
|
Officer • CHIEF DEVELOPMENT OFFICER
Sell to Cover
|
2026-02-23 | $67,669 | S | Form 4 |
|
KALV
S
KalVista Pharmaceuticals, Inc.
Audhya Paul K.
• Officer • CHIEF MEDICAL OFFICER
Sell to Cover
2026-02-18
$17,445
|
||||||
| KALV |
KalVista Pharmaceuticals, Inc.
|
Officer • CHIEF MEDICAL OFFICER
Sell to Cover
|
2026-02-18 | $17,445 | S | Form 4 |
| KALV |
KalVista Pharmaceuticals, Inc.
|
CEO
Sell to Cover
|
2026-02-18 | $15,570 | S | Form 4 |
|
KALV
S
KalVista Pharmaceuticals, Inc.
Yea Christopher
• Officer • CHIEF DEVELOPMENT OFFICER
Sell to Cover
2026-02-18
$16,635
|
||||||
| KALV |
KalVista Pharmaceuticals, Inc.
|
Officer • CHIEF DEVELOPMENT OFFICER
Sell to Cover
|
2026-02-18 | $16,635 | S | Form 4 |
| KALV |
KalVista Pharmaceuticals, Inc.
|
CEO
Sell to Cover
|
2026-02-12 | $52,658 | S | Form 4 |
|
KALV
S
KalVista Pharmaceuticals, Inc.
Audhya Paul K.
• Officer • CHIEF MEDICAL OFFICER
Sell to Cover
2025-11-24
$71,236
|
||||||
| KALV |
KalVista Pharmaceuticals, Inc.
|
Officer • CHIEF MEDICAL OFFICER
Sell to Cover
|
2025-11-24 | $71,236 | S | Form 4 |
| KALV |
KalVista Pharmaceuticals, Inc.
|
CEO
Sell to Cover
|
2025-11-24 | $147,154 | S | Form 4 |
|
KALV
S
KalVista Pharmaceuticals, Inc.
Piekos Brian
• CFO
Sell to CoverΔOwn -29.8%
2025-11-24
$60,139
|
||||||
| KALV |
KalVista Pharmaceuticals, Inc.
|
CFO
Sell to CoverΔOwn -29.8%
|
2025-11-24 | $60,139 | S | Form 4 |
|
KALV
S
KalVista Pharmaceuticals, Inc.
Sweeny Nicole
• Officer • Chief Commercial Officer
Sell to Cover
2025-11-24
$51,289
|
||||||
| KALV |
KalVista Pharmaceuticals, Inc.
|
Officer • Chief Commercial Officer
Sell to Cover
|
2025-11-24 | $51,289 | S | Form 4 |
|
KALV
S
KalVista Pharmaceuticals, Inc.
Yea Christopher
• Officer • CHIEF DEVELOPMENT OFFICER
Sell to Cover
2025-11-24
$58,256
|
||||||
| KALV |
KalVista Pharmaceuticals, Inc.
|
Officer • CHIEF DEVELOPMENT OFFICER
Sell to Cover
|
2025-11-24 | $58,256 | S | Form 4 |
|
KALV
S
KalVista Pharmaceuticals, Inc.
Audhya Paul K.
• Officer • CHIEF MEDICAL OFFICER
Sell to Cover
2025-11-18
$44,524
|
||||||
| KALV |
KalVista Pharmaceuticals, Inc.
|
Officer • CHIEF MEDICAL OFFICER
Sell to Cover
|
2025-11-18 | $44,524 | S | Form 4 |
| KALV |
KalVista Pharmaceuticals, Inc.
|
CEO
Sell to Cover
|
2025-11-18 | $64,665 | S | Form 4 |
|
KALV
S
KalVista Pharmaceuticals, Inc.
Yea Christopher
• Officer • CHIEF DEVELOPMENT OFFICER
Sell to Cover
2025-11-18
$38,848
|
||||||
| KALV |
KalVista Pharmaceuticals, Inc.
|
Officer • CHIEF DEVELOPMENT OFFICER
Sell to Cover
|
2025-11-18 | $38,848 | S | Form 4 |
| KALV |
KalVista Pharmaceuticals, Inc.
|
CEO
Sell to Cover
|
2025-11-12 | $38,438 | S | Form 4 |